CapsoVision to Release Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 26, 2026
Rhea-AI Summary
CapsoVision (NASDAQ: CV) will release fourth quarter and full year 2025 financial results on Thursday, March 26, 2026, after market close.
The company will host a conference call and live webcast on March 26, 2026 at 1:30 pm PT / 4:30 pm ET to discuss results and provide a corporate update. Dial-in numbers: (800) 715-9871 (US) or (646) 307-1963 (international); conference ID 2525025. The webcast replay will be available for one year via the Events page in investor relations; registration required to access the replay.
Positive
- None.
Negative
- None.
News Market Reaction – CV
In the Mar 13 session, CV gained 2.99%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 09 | Investor conference | Neutral | +1.8% | ROTH Conference participation with fireside chat and 1x1 investor meetings. |
| Dec 29 | Regulatory submission | Positive | +7.0% | 510(k) submission for AI-assisted reading module in CapsoCam Plus. |
| Nov 20 | Investor conference | Neutral | -1.9% | Benchmark investor conference participation with senior management meetings. |
| Nov 13 | Quarterly earnings | Positive | -9.7% | Q3 2025 financial results with revenue growth and operating expense increases. |
| Nov 10 | Regulatory update | Positive | +10.2% | Breakthrough Device Designation application for pancreatic cancer capsule. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Most recent news, including regulatory and conference updates, has produced moves aligned with generally positive or neutral sentiment, with one notable divergence on earnings.
Over the last six months, CapsoVision has mixed corporate and regulatory milestones with investor outreach. A November 10, 2025 update on a Breakthrough Device Designation application for a pancreatic cancer screening capsule and a December 29, 2025 510(k) submission for an AI-assisted reading module both coincided with positive price reactions. Participation in investor conferences on November 20, 2025 and March 9, 2026 saw more modest moves. By contrast, the November 13, 2025 Q3 2025 earnings press release drew a negative reaction, indicating sensitivity around financial updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call Scheduled for Thursday, March 26, 2026, at 4:30 pm ET
SARATOGA, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the company will release fourth quarter and full year 2025 financial results on Thursday, March 26, 2026, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update.
Individuals interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and referencing conference ID 2525025, or from the webcast link on the Events page in the investor relations section of the company’s website.
To access the replay, please register via the webcast link on the Events page. The webcast will be available for one year following the completion of the call.
About CapsoVision
CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and screening of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company’s next pipeline product, CapsoCam Colon™ with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit www.capsovision.com.
Investor Relations Contact
Leigh Salvo
New Street Investor Relations
Investors@CapsoVision.com
Media Contact
Leslie Strickler and Paul Spicer
Être Communications
leslies@etrecommunications.com | (804) 240-0807
pauls@etrecommunications.com | (804) 503-9231
